Market capitalization | $3.46b |
Enterprise Value | $3.64b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.99 |
P/S ratio (TTM) P/S ratio | 7.58 |
P/B ratio (TTM) P/B ratio | 26.06 |
Revenue growth (TTM) Revenue growth | 29.98% |
Revenue (TTM) Revenue | $455.66m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
13 Analysts have issued a Amicus Therapeutics, Inc. forecast:
13 Analysts have issued a Amicus Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 456 456 |
30%
30%
|
|
Gross Profit | 401 401 |
31%
31%
|
|
EBITDA | -17 -17 |
86%
86%
|
EBIT (Operating Income) EBIT | -25 -25 |
80%
80%
|
Net Profit | -120 -120 |
35%
35%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
Head office | United States |
CEO | Bradley Campbell |
Employees | 517 |
Founded | 2002 |
Website | www.amicusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.